Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Breast Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Genetic Profile × Clear all
NCT05455606 2026-01-22

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

SWOG Cancer Research Network

Phase NA Active not recruiting
1,284 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05385081 2022-05-23

PRECODE

Odense University Hospital

Phase NA Unknown
900 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡